AL137-ABC
Alzheimer's Disease
PreclinicalActive
Key Facts
About Alector
Founded in 2013 and publicly traded on Nasdaq, Alector is on a mission to slow and prevent neurodegenerative diseases by harnessing insights from human genetics, immunology, and neuroscience. The company has built a robust pipeline of potential first- and best-in-class candidates, with its lead program, latozinemab (AL001), in a pivotal Phase 3 trial for frontotemporal dementia and AL101 in Phase 2 for Alzheimer's disease via a major collaboration with GSK. Alector's strategy combines internal R&D with high-value partnerships, supported by a seasoned leadership team with deep expertise in drug discovery and development.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |